Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 15, 2022 - Issue 2
Submit an article Journal homepage
9,277
Views
22
CrossRef citations to date
0
Altmetric
Drug Profile

Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause

Céline Gérarda Department Research and Development, Estetra Srl, an Affiliate Company of Mithra Pharmaceuticals, Liège, BelgiumView further author information
,
Jean-François Arnalb CHU de Toulouse, Université Toulouse III, Toulouse, France;c INSERM-UPS UMR U1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de Toulouse, Toulouse, FranceView further author information
,
Maud Josta Department Research and Development, Estetra Srl, an Affiliate Company of Mithra Pharmaceuticals, Liège, BelgiumView further author information
,
Jonathan Douxfilsd Qualiblood S.a, Namur, Belgium;e Department of Pharmacy, Namur Thrombosis and Hemostasis Center, NAmur Research Institute for Life Sciences, University of Namur, Namur, BelgiumORCID Iconhttps://orcid.org/0000-0002-7644-5298View further author information
ORCID Icon,
Françoise Lenfantb CHU de Toulouse, Université Toulouse III, Toulouse, France;c INSERM-UPS UMR U1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de Toulouse, Toulouse, FranceView further author information
,
Coralie Fontaineb CHU de Toulouse, Université Toulouse III, Toulouse, France;c INSERM-UPS UMR U1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de Toulouse, Toulouse, FranceView further author information
,
René Houtmanf Precision Medicine Lab, Oss, The NetherlandsView further author information
,
David F. Archerg Eastern Virginia Medical School, Norfolk, USAView further author information
,
Robert L. Reidh Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynaecology, Queen’s University, Kingston, CanadaView further author information
,
Rogerio A. Loboi Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, USAView further author information
,
Ulysse Gaspardj Department of Obstetrics and Gynecology, University of Liège, Liège, BelgiumView further author information
,
Herjan J.T. Coelingh Benninkk Pantarhei Oncology, Zeist, The NetherlandsView further author information
,
Mitchell D. Creininl Department of Obstetrics and Gynecology, University of California, Sacramento, USAORCID Iconhttps://orcid.org/0000-0001-5967-8180View further author information
ORCID Icon &
Jean-Michel Foidarta Department Research and Development, Estetra Srl, an Affiliate Company of Mithra Pharmaceuticals, Liège, Belgium;j Department of Obstetrics and Gynecology, University of Liège, Liège, BelgiumCorrespondence[email protected]
View further author information
 show all
Pages 121-137 | Received 28 Sep 2021, Accepted 14 Mar 2022, Published online: 27 Mar 2022

References

  • Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011;11(8):597–608.
  • Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006;116(3):242–246.
  • Arnal JF, Lenfant F, Metivier R, et al. Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications. Physiol Rev. 2017;97(3):1045–1087.
  • Valera MC, Fontaine C, Dupuis M, et al. Towards optimization of estrogen receptor modulation in medicine. Pharmacol Ther. 2018;189:123–129.
  • Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev. 2013;34(3):309–338.
  • Frobenius W. The rabbits are prepared … ” - the development of ethinylestradiol and ethinyltestosterone. J Reproduktionsmed Endokrinol. 2011;8(Suppl.1):32–57.
  • Lidegaard O, Lokkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.
  • Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011;343:d6423.
  • Morch LS, Skovlund CW, Hannaford PC, et al. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228–2239.
  • Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women’s health initiative randomized trial. JAMA. 2003;289(24):3243–3253.
  • Manson JE, Kaunitz AM. Menopause management–getting clinical care back on track. N Engl J Med. 2016;374(9):803–806.
  • Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the qResearch and CPRD databases. BMJ. 2019;364:k4810.
  • Hagen AA, Barr M, Diczfalusy E. Metabolism of 17-beta-oestradiol-4-14-C in early infancy. Acta Endocrinol (Copenh). 1965;49:15–21.
  • Gurpide E, Schwers J, Welch MT, et al. Fetal and maternal metabolism of estradiol during pregnancy. J Clin Endocrinol Metab. 1966;26(12):1355–1365.
  • Schwers J, Eriksson G, Diczfalusy E. 15 alpha-hydroxylation: a new pathway of estrogen metabolism in the human fetus and newborn. Biochim Biophys Acta. 1965;100:313–316.
  • Schwers J, Govaerts-Videtsky M, Wiqvist N, et al. Metabolism of oestrone sulphate by the previable human foetus. Acta Endocrinol (Copenh). 1965;50(4):597–610.
  • Holinka CF, Gurpide E. In vivo effects of estetrol on the immature rat uterus. Biol Reprod. 1979;20(2):313–316.
  • Holinka CF, Bressler RS, Zehr DR, et al. Comparison of effects of estetrol and tamoxifen with those of estriol and estradiol on the immature rat uterus. Biol Reprod. 1980;22(4):913–926.
  • Coelingh Bennink HJ, Holinka CF, Diczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric. 2008;Suppl 11:47–58.
  • Warmerdam EG, Visser M, Coelingh Bennink HJ, et al. A new route of synthesis of estetrol. Climacteric. 2008;Suppl 11:59–63.
  • Estetra SA. Process for the production of estetrol intermediates. International patent application WO 2012/164096 A1; 2012 Jun 1.
  • Gemzell Danielsson K, Apter D, Zatik J, et al. Estetrol-drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern, and safety in Europe and Russia. Br J Obstet Gynaecol. 2022;129(1):63–71.
  • Creinin MD, Westhoff CL, Bouchard C, et al. Estetrol-drospirenone combination oral contraceptive: north American phase 3 efficacy and safety results. Contraception. 2021;104(3):222. .
  • Estetra SPRL. A randomized double-blind placebo controlled phase 3 trial to evaluate the efficacy and safety of estetrol for the treatment of moderate to severe vasomotor symptoms in postmenopausal women (E4Comfort Study I). EUDRACT 2019-001289-14. Clinicaltrials.gov NCT04209543.
  • Estetra SPRL. A randomized double-blind placebo controlled phase 3 trial to evaluate the efficacy and safety of estetrol for the treatment of moderate to severe vasomotor symptoms in postmenopausal women (E4Comfort Study II). Clinicaltrials.Gov NCT04090957.
  • Utian WH, Lobo R, Mawet M, et al. A phase 3 protocol to assess the efficacy and safety of estetrol (E4), a promising new treatment for menopausal vasomotor symptoms. Menopause. 2019;26(12):1480.
  • Gaspard U, Taziaux M, Jost M, et al. Estetrol (E4), the next generation hormone therapy (HT) for menopausal symptoms: phase 2b clinical trial results. 12th European Congress on Menopause and Andropause. Berlin, Germany. Maturitas. 2019 May 15-17;124(153): Abstract P09.
  • Gaspard U, Taziaux M, Mawet M, et al. A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety. Menopause. 2020;27(8): 848–857
  • Schmidt M, Lenhard H, Hoenig A, et al. Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer. J Cancer Res Clin Oncol. 2021;147(6):1833–1842.
  • Coelingh Bennink HJT, Van Moorselaar JA, Crawford ED, et al. Estetrol cotreatment of androgen deprivation therapy in infiltrating or metastatic, castration-sensitive prostate cancer: a randomized, double-blind, phase II trial (PCombi). Eur Urol Open Sci. 2021; 28: 52–61.
  • Coelingh Bennink F, Holinka CF, Visser M, et al. Maternal and fetal estetrol levels during pregnancy. Climacteric. 2008;Suppl 11:69–72.
  • Hickey M, Hart R, Keelan JA. The relationship between umbilical cord estrogens and perinatal characteristics. Cancer Epidemiol Biomarkers Prev. 2014;23(6):946–952.
  • Visser M, Holinka CF, Coelingh Bennink HJ. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women. Climacteric. 2008;Suppl 11:31–40.
  • Nextstellis. Prescibing information. [cited Jul 2021]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214154s000lbl.pdf
  • Drovelis (estetrol/drospirenone). Summary of product characteristics [cited Jul 2021]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/drovelis
  • Santen RJ, Yue W, Wang JP. Estrogen metabolites and breast cancer. Steroids. 2015;99(Pt A):61–66.
  • Yager JD. Mechanisms of estrogen carcinogenesis: the role of E2/E1-quinone metabolites suggests new approaches to preventive intervention–a review. Steroids. 2015;99(Pt A):56–60.
  • Bagot CN, Marsh MS, Whitehead M, et al. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J Thromb Haemost. 2010;8(8):1736–1744.
  • Pugeat MM, Dunn JF, Nisula BC. Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981;53(1):69–75.
  • Hodgert Jury H, Zacharewski TR, Hammond GL. Interactions between human plasma sex hormone-binding globulin and xenobiotic ligands. J Steroid Biochem Mol Biol. 2000;75(2–3):167–176.
  • Hammond GL, Hogeveen KN, Visser M, et al. Estetrol does not bind sex hormone binding globulin or increase its production by human HepG2 cells. Climacteric. 2008;Suppl 11:41–46.
  • Siiteri PK, Murai JT, Hammond GL, et al. The serum transport of steroid hormones. Recent Prog Horm Res. 1982;38:457–510.
  • Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA. 2005;293(3):330–339.
  • Jirku H, Kadner S, Levitz M. Pattern of estetrol conjugation in the human. Steroids. 1972;19(4):519–534.
  • Nagatomi K, Osawa Y, Kirdani RY, et al. Studies on phenolic steroids in human subjects. XVII. The kidney and fate of 1 5 alpha-hydroxyestrogens. J Clin Endocrinol Metab. 1973;37(6):887–900.
  • Schut HA, Bowman JM, Solomon S. Precursor role of 15 alpha-hydroxyestradiol and 15alpha-hydroxyandrostenedione in the formation of estetrol. Can J Biochem. 1978;56(2):887–900.
  • Coelingh Bennink HJT, Foidart JM. Estetrol, a fetal steroid for the treatment of adults. J Reprod Med Endokrinol Online. 2015;12(4):399–403.
  • Abot A, Fontaine C, Buscato M, et al. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor alpha modulation, uncoupling nuclear and membrane activation. EMBO Mol Med. 2014;6(10):1328–1346. •Describes the characterisation of E4 as an selective ER modulator.
  • Levin ER, Pietras RJ. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat. 2008;108(3):351–361.
  • Mendelsohn ME, Karas RH. Rapid progress for non-nuclear estrogen receptor signaling. J Clin Invest. 2010;120(7):2277–2279.
  • Wu Q, Chambliss K, Umetani M, et al. Non-nuclear estrogen receptor signaling in the endothelium. J Biol Chem. 2011;286(17):14737–14743.
  • Darblade B, Caillaud D, Poirot M, et al. Alteration of plasmalemmal caveolae mimics endothelial dysfunction observed in atheromatous rabbit aorta. Cardiovasc Res. 2001;50(3):566–576.
  • Zhang D, Trudeau VL. Integration of membrane and nuclear estrogen receptor signaling. Comp Biochem Physiol A Mol Integr Physiol. 2006;144(3):306–315.
  • Gerard C, Mestdagt M, Tskitishvili E, et al., Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms. Oncotarget. 6(19): 17621–17636. 2015.
  • Marino M, Ascenzi P. Membrane association of estrogen receptor alpha and beta influences 17beta-estradiol-mediated cancer cell proliferation. Steroids. 2008;73(9–10):853–858.
  • Zimmerman MA, Budish RA, Kashyap S, et al. GPER-novel membrane oestrogen receptor. Clin Sci (Lond). 2016;130(12):1005–1016.
  • Giretti MS, Montt Guevara MM, Cecchi E, et al. Effects of estetrol on migration and invasion in T47D breast cancer cells through the actin cytoskeleton. Front Endocrinol (Lausanne). 2014;5:80.
  • Montt-Guevara MM, Giretti MS, Russo E, et al. Estetrol modulates endothelial nitric oxide synthesis in human endothelial cells. Front Endocrinol (Lausanne). 2015;6:111.
  • Pluchino N, Santoro AN, Casarosa E, et al. Effect of estetrol administration on brain and serum allopregnanolone in intact and ovariectomized rats. J Steroid Biochem Mol Biol. 2014;143:285–290.
  • Tskitishvili E, Nisolle M, Munaut C, et al. Estetrol attenuates neonatal hypoxic-ischemic brain injury. Exp Neurol. 2014;261:298–307.
  • Coelingh Bennink HJ, Heegaard AM, Visser M, et al. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. Climacteric. 2008;Suppl 11:2–14.
  • Coelingh Bennink HJ, Skouby S, Bouchard P, et al. Ovulation inhibition by estetrol in an in vivo model. Contraception. 2008;77((3)):186–190.
  • Guivarc’h E, Buscato M, Guihot A-L, et al. Predominant Role of Nuclear Versus Membrane Estrogen Receptor α in Arterial Protection: implications for Estrogen Receptor α Modulation in Cardiovascular Prevention/Safety. J Am Heart Assoc. 2018;7(13):e008950.
  • Wardell SE, Marks JR, McDonnell DP. The turnover of estrogen receptor alpha by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem Pharmacol. 2011;82(2):122–130.
  • Benoit T, Valera MC, Fontaine C, et al. Estetrol, a fetal selective estrogen receptor modulator, acts on the vagina of mice through nuclear estrogen receptor alpha activation. Am J Pathol. 2017;187(11):2499–2507.
  • Adlanmerini M, Solinhac R, Abot A, et al. Mutation of the palmitoylation site of estrogen receptor alpha in vivo reveals tissue-specific roles for membrane versus nuclear actions. Proc Natl Acad Sci U S A. 2014;111(2):E283–90.
  • Komm BS, Mirkin S. An overview of current and emerging SERMS. J Steroid Biochem Mol Biol. 2014;143:207–222.
  • Heery DM, Kalkhoven E, Hoare S, et al. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997;387(6634):733–736.
  • Metivier R, Stark A, Flouriot G, et al. A dynamic structural model for estrogen receptor-alpha activation by ligands, emphasizing the role of interactions between distant A and E domains. Mol Cell. 2002;10(5):1019–1032.
  • Katzenellenbogen BS, Sun J, Harrington WR, et al. Structure-function relationships in estrogen receptors and the characterization of novel selective estrogen receptor modulators with unique pharmacological profiles. Ann N Y Acad Sci. 2001;949:6–15.
  • Broekema MF, Hollman DAA, Koppen A, et al. Profiling of 3696 nuclear receptor-coregulator interactions: a resource for biological and clinical discovery. Endocrinology. 2018;159(6):2397–2407.
  • Guan J, Zhou W, Hafner M, et al. Therapeutic ligands antagonize estrogen receptor function by impairing its mobility. Cell. 2019;178(4):949–963 e18.
  • Nwachukwu JC, Srinivasan S, Zheng Y, et al. Predictive features of ligand-specific signaling through the estrogen receptor. Mol Syst Biol. 2016;12(4):864.
  • Foidart JM, Arnal J, Lenfant F, et al. Estetrol (E4) is a unique estrogen with selective actions in tissues which are distinctly different from the actions of SERMs. Menopause. 2019;26:1464–1465.
  • Foidart JM, Arnal JF, Lenfant F, et al. Estetrol (E4) is a unique estrogen with selective actions in tissues which are distinctly different from the actions of SERMs. J Endocr Soc. 2019;3(Suppl.1):SUN–LB001.
  • Foidart JM, Gaspard U, Pequeux C, et al. Unique vascular benefits of estetrol, a native fetal estrogen with specific actions in tissues (NEST). In: Diaz Brinton RD, Genazzani AR, Simoncini T, et al.editors. Sex steroids’ effects on brain, heart and vessels: volume 6: frontiers in gynecological endocrinology. Cham: Springer International Publishing; 2019. p. 169–195.
  • Yasar P, Ayaz G, User SD, et al. Molecular mechanism of estrogen-estrogen receptor signaling. Reprod Med Biol. 2017;16(1):4–20.
  • Duijkers IJM, Klipping C, Zimmerman Y, et al. Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: results of a phase II dose-finding pilot study. Eur J Contracept Reprod Health Care. 2015;20(6):476–489.
  • Apter D, Zimmerman Y, Beekman L, et al. Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. Eur J Contracept Reprod Health Care. 2017;22(4):260–267.
  • Apter D, Zimmerman Y, Beekman L, et al. Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA). Contraception. 2016;94:366–373.
  • Duijkers I, Klipping C, Kinet V, et al., Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function. Contraception. 103(6): 386–393. 2021.
  • Mawet M, Maillard C, Klipping C, et al. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. Eur J Contracept Reprod Health Care. 2015;20(6):463–475.
  • Klipping C, Duijkers I, Mawet M, et al., Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 103(4): 213–221. 2021.
  • Douxfils J, Klipping C, Duijkers I, et al., Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. Contraception. 102(6): 396–402. 2020.
  • Kluft C, Zimmerman Y, Mawet M, et al. Reduced haemostatic effects with drospirenone-based oral contraceptives containing estetrol versus ethinyl estradiol. Contraception. 2017;95(2):140–147.
  • Coelingh Bennink HJT, Zimmerman Y, Verhoeven C, et al. Clinical effects of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women. Maturitas. 2016;91:93–100.
  • Dragoman MV, Tepper NK, Fu R, et al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet. 2018;141(3):287–294.
  • Mantha S, Karp R, Raghavan V, et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012;345(aug07 2):e4944.
  • Foidart JM, Lobo RA, Rosing J, et al. Estetrol (E4) is a unique native estrogen that does not modify coagulation markers in postmenopausal women and maintains sensitivity to activated protein C (APC). Menopause. 2019;26(12):1464–1465.
  • Morimont L, Dogne JM, Douxfils J. Letter to the editors-in-chief in response to the article of Abou-Ismail, et al. Entitled “estrogen and thrombosis: a bench to bedside review. Thromb Res. 2020;193(193):221–223. (Thrombosis Research 192 (2020) 40-51).
  • Morimont L, Haguet H, Dogné J-M, et al. Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk. Front Endocrinol (Lausanne). 2021; 12. 1592 https://doi.org/10.3389/fendo.2021.769187
  • Shapiro S. Oral contraceptives, hormone therapy and cardiovascular risk. Climacteric. 2008;11(5):355–363.
  • Valera MC, Gratacap MP, Gourdy P, et al. Chronic estradiol treatment reduces platelet responses and protects mice from thromboembolism through the hematopoietic estrogen receptor alpha. Blood. 2012;120(8):1703–1712.
  • Valera MC, Fontaine C, Lenfant F, et al. Protective hematopoietic effect of estrogens in a mouse model of thrombosis: respective roles of nuclear versus membrane estrogen receptor alpha. Endocrinology. 2015;156(11):4293–4301.
  • Valera MC, Noirrit-Esclassan E, Dupuis M, et al. Effect of estetrol, a selective nuclear estrogen receptor modulator, in mouse models of arterial and venous thrombosis. Mol Cell Endocrinol. 2018;477:132–139.
  • Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids. 1996;61(4):166–171.
  • Oelkers W, Blumel A, Schoneshofer M, et al. Effects of ethinylestradiol on the renin-angiotensin-aldosterone-system and on plasma transcortin in women and men. J Clin Endocrinol Metab. 1976;43(5):1036–1040.
  • Crane MG, Harris JJ. Effect of estrogens and gestagens on the renin–aldosterone system in oral contraceptives and high blood pressure. In: Fregly MJ, Fregly MS, editors. Oral contraceptives and high blood pressure. Gainesville: Dolphin press; 1974. p. 100–119.
  • Crane MG, Harris JJ. Effect of estrogens and gestagens on exchangeable sodium. In: Fregly MJ, Fregly MS, editors. Oral contraceptives and high blood pressure. Gainesville: Dolphin press; 1974. p. 159–168.
  • Oelkers W, Schoneshofer M, Blumel A. Effects of progesterone and four synthetic progestagens on sodium balance and the renin-aldosterone system in man. J Clin Endocrinol Metab. 1974;39(5):882–890.
  • Oelkers W, Berger V, Bolik A, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab. 1991;73(4):837–842.
  • Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995;80(6):1816–1821.
  • Foidart JM. Added benefits of drospirenone for compliance. Climacteric. 2005;8(3):28–34.
  • Fan P, Jordan VC. New insights into acquired endocrine resistance of breast cancer. Cancer Drug Resist. 2019;2:198–209.
  • Yue W, Verhoeven C, Bernnink HC, et al. Pro-Apoptotic Effects of Estetrol on Long-Term Estrogen-Deprived Breast Cancer Cells and at Low Doses on Hormone-Sensitive Cells. Breast Cancer : Basic and Clinical Research. 2019;13:1178223419844198.
  • Abderrahman B, Maximov PY, Curpan RF, et al. Rapid induction of the unfolded protein response and apoptosis by estrogen mimic TTC-352 for the treatment of endocrine-resistant breast cancer. Mol Cancer Ther. 2021;20(1):11–25.
  • Gerard C, Blacher S, Communal L, et al. Estetrol is a weak estrogen antagonizing estradiol-dependent mammary gland proliferation. J Endocrinol. 2015;224(1):85–95.
  • Coelingh Bennink HJT, Singer C, Simoncini T, et al. Estetrol, a pregnancy-specific human steroid, prevents and suppresses mammary tumor growth in a rat model. Climacteric. 2008;11(Suppl.1):29.
  • Gallez A, Blacher S, Maquoi E, et al. Estetrol combined to progesterone for menopause or contraception indication is neutral on breast cancer. Cancers (Basel). 2021;13:2486.
  • Singer CF, Bennink HJ, Natter C, et al. Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer. Carcinogenesis. 2014;35(11):2447–2451.
  • Smirnova NF, Fontaine C, Buscato M, et al. The activation function-1 of estrogen receptor alpha prevents arterial neointima development through a direct effect on smooth muscle cells. Circ Res. 2015;117(9):770–778.
  • Favre J, Vessieres E, Guihot AL, et al. Membrane estrogen receptor alpha (ERα) participates in flow-mediated dilation in a ligand-independent manner. ELife. 2021;10. https://doi.org/10.7554/eLife.68695.
  • Vanhoutte PM. Nitric oxide: from good to bad. Ann Vasc Dis. 2018;11(1):41–51.
  • Vanhoutte PM, Zhao Y, Xu A, et al. Thirty years of saying no: sources, fate, actions, and misfortunes of the endothelium-derived vasodilator mediator. Circ Res. 2016;119(2):375–396.
  • Yamazaki Y, Kondo Y, Kamiyama Y. Estimation of shear-stress-induced endothelial nitric oxide production from flow-mediated dilation. Annu Int Conf IEEE Eng Med Biol Soc. 2013;2013:41–51.
  • Levine MG, Miodovnik M, Clark KE. Uterine vascular effects of estetrol in nonpregnant ewes. Am J Obstet Gynecol. 1984;148(6):735–738.
  • Hilgers RH, Oparil S, Wouters W, et al. Vasorelaxing effects of estetrol in rat arteries. J Endocrinol. 2012;215(1):97–106.
  • Zahreddine R, Davezac M, Smirnova N, et al. Tamoxifen accelerates endothelial healing by targeting ERα in smooth muscle cells. Circ Res. 2020;127(12):1473–1487.
  • Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88(6):29.
  • Mauvais-Jarvis F, Manson JE, Stevenson JC, et al. Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications. Endocr Rev. 2017;38(3):173–188.
  • Thong EP, Codner E, Laven JSE, et al. Diabetes: a metabolic and reproductive disorder in women. Lancet Diabetes Endocrinol. 2020;8(2):134–149.
  • Buscato M, Davezac M, Zahreddine R, et al. Estetrol prevents western diet-induced obesity and atheroma independently of hepatic estrogen receptor alpha. Am J Physiol Endocrinol Metab. 2021;320(1):E19–E29.
  • Archer DF, Nakajima ST, Sawyer AT, et al. Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive. Obstet Gynecol. 2013;122(3):E19–E29.
  • Trussell J, Portman D. The creeping pearl: why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills? Contraception. 2013;88(5):604–610.
  • Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost. 2003;89(3):493–498.
  • Gemzell-Danielsson K, Sitruk-Ware R, Creinin MD, et al. Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation. Contraception. 2019;99(6):323–328.
  • Nelson AL, Kaunitz AM, Kroll R, et al. Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: phase 3 clinical trial results. Contraception. 2021;103(3):137–143.
  • Holinka CF, Brincat M, Coelingh Bennink HJ. Preventive effect of oral estetrol in a menopausal hot flush model. Climacteric. 2008;Suppl 11:15–21.
  • Utian WH, Gaspard U, Jost M, et al. Estetrol, the next generation of hormone therapy: results of a phase 2b dose-finding study in postmenopausal women (E4 Relief). Menopause. 2018;25:1489–1490.
  • Schneider HP, Heinemann LA, Rosemeier HP, et al. The menopause rating scale (MRS): reliability of scores of menopausal complaints. Climacteric. 2000;3(1):59–64.
  • Tskitishvili E, Pequeux C, Munaut C, et al. Estrogen receptors and estetrol-dependent neuroprotective actions: a pilot study. J Endocrinol. 2017;232(1):85–95.
  • Prokai-Tatrai K, Perjesi P, Rivera-Portalatin NM, et al. Mechanistic investigations on the antioxidant action of a neuroprotective estrogen derivative. Steroids. 2008;73(3):280–288.
  • Tskitishvili E, Foidart JM. Estetrol and its effects on the damaged brain. In: Diaz Brinton R, Genazzani AR, Simoncini T, et al., editors. Sex steroids’ effects on brain, heart and vessels: volume 6: frontiers in gynecological endocrinology. Cham: Springer International Publishing; 2019. p. 43–92.
  • Tskitishvili E, Pequeux C, Munaut C, et al. Use of estetrol with other steroids for attenuation of neonatal hypoxic-ischemic brain injury: to combine or not to combine? Oncotarget. 2016;7(23):33722–33743.
  • Yang S, Fang Z, Gurates B, et al. Stromal PRs mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2. Mol Endocrinol. 2001;15(12):2093–2105.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.